Clusterin maintains hemostatic equilibrium by stabilizing VWF multimers in plasma

Area of Science:

• Vascular Biology and Hemostasis
• Endothelial Cell Biology
• Proteomics and Molecular Medicine

Background:

• The balance between blood coagulation and anticoagulation is critical for hemostasis.
• Endothelial-derived factors regulating this balance are not fully understood.
• Weibel-Palade bodies (WPBs) are known storage sites for hemostatic factors.

Purpose of the Study:

• To identify novel endothelial-derived factors involved in hemostatic regulation.
• To elucidate the role of clusterin in maintaining von Willebrand factor (VWF) multimer stability.
• To explore clusterin as a potential therapeutic target for bleeding disorders.

Main Methods:

• Proteomic analysis of the endothelial secretome.
• Immunostaining and co-transfection assays to identify WPB components.
• Studies in clusterin-deficient mice and von Willebrand disease (VWD) patient plasma.
• Biochemical assays to determine the mechanism of clusterin-VWF interaction.

Main Results:

• Clusterin was identified as a WPB component and secreted factor crucial for VWF multimer stabilization.
• Reduced clusterin levels were observed in type 2A VWD patient plasma.
• Clusterin deficiency in mice caused bleeding and impaired thrombosis due to reduced high molecular weight (HMW) VWF.
• Clusterin binds to VWF, inhibiting ADAMTS13 proteolysis and preserving HMW VWF multimers.

Conclusions:

• Clusterin is a key regulator of VWF multimer quality, essential for hemostatic equilibrium.
• WPBs serve as hubs for regulatory proteins like clusterin.
• Clusterin stabilization of VWF offers a novel therapeutic approach for bleeding disorders, shifting focus from protein replacement to multimer quality.